VG203
/ ViroGin Biotech
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
November 08, 2023
Latest development, VG203 another attenuated backbone oncolytic virus product from Fornogen has been approved for clinical trials in China [Google translation]
(CPHI.cn)
- "...Fornogen announced that the company's second new generation non-attenuated backbone oncolytic virus product VG203 (product number VG2062) has received implicit clinical trial approval from the Center for Drug Evaluation of the National Medical Products Administration, approving it to conduct Phase I clinical trials in China."
New P1 trial • Oncology • Solid Tumor
1 to 1
Of
1
Go to page
1